BRCA1 rs4986850: Understanding This Genetic Variant
The rs4986850 variant is a specific genetic marker located within the BRCA1 gene region. It has been identified in research as one of many SNPs contributing to cumulative breast cancer risk assessments.
What each genotype means
Average risk profile
This genotype represents the common reference state for this variant in the BRCA1 gene. Research suggests this variant is one of 25 SNPs that may contribute to cumulative breast cancer risk, but this specific genotype is not associated with the increased risk observed with the minor allele.
This is the most common genotype observed in most global populations.
Slightly elevated risk marker
Carrying one copy of the minor allele (A) is associated with a minor, cumulative contribution to breast cancer risk as part of a larger 25-SNP panel. This finding is based on limited evidence and should not be interpreted as a diagnostic indicator of hereditary cancer syndromes.
Carried by a small percentage of the population, consistent with a global minor allele frequency of approximately 0.039.
Elevated risk marker
Carrying two copies of the minor allele (A) is associated with a minor, cumulative contribution to breast cancer risk when considered alongside other genetic factors. The clinical significance of this variant is currently categorized as limited, and it does not independently predict hereditary breast or ovarian cancer syndrome.
This homozygous genotype is rare, occurring in a small fraction of the population based on the reported minor allele frequency.
What is rs4986850?
The rs4986850 variant is a single nucleotide polymorphism (SNP) located within the genomic region of the BRCA1 gene. In genetics, a SNP represents a variation at a single position in the DNA sequence among individuals. While many SNPs are neutral, researchers study specific variants like rs4986850 to determine if they correlate with particular health traits or disease susceptibilities. This specific variant is often analyzed as part of larger, multi-SNP panels designed to estimate polygenic risk scores for breast cancer. Because it is part of a panel rather than a single high-impact mutation, its individual contribution to risk is considered modest and requires context from other genetic and environmental factors.
The Role of the BRCA1 Gene
The BRCA1 gene provides instructions for making a protein that acts as a tumor suppressor. This protein is essential for repairing damaged DNA, which helps maintain the stability of a cell's genetic information. When the BRCA1 protein functions correctly, it prevents cells from growing and dividing too rapidly or in an uncontrolled way. Pathogenic mutations in BRCA1 are well-known for significantly increasing the risk of breast and ovarian cancers. However, it is important to distinguish between rare, high-penetrance pathogenic mutations and common variants like rs4986850. While the gene itself is critical for cancer prevention, common variants within or near the gene often have much smaller, more nuanced effects on overall risk compared to the rare, high-risk mutations.
Research and Evidence Strength
The evidence linking rs4986850 to breast cancer risk is currently classified as limited. Scientific studies, including genome-wide association studies (GWAS), often identify thousands of variants that show statistical associations with complex diseases. rs4986850 is frequently included in panels that look at the cumulative effect of many small-effect variants. Because breast cancer is a complex condition influenced by hundreds of genetic markers, lifestyle, and environmental factors, the predictive power of any single SNP like rs4986850 is generally low. Researchers emphasize that these associations are statistical in nature and do not imply a direct cause-and-effect relationship for every individual. Further large-scale studies are necessary to fully understand the biological mechanism, if any, by which this specific variant might influence cancer susceptibility.
Population Frequency
Genetic variants are distributed differently across global populations, and understanding these frequencies is key to interpreting genetic data. The Global Minor Allele Frequency (GMAF) for rs4986850 is approximately 0.03949. This indicates that the variant is relatively uncommon in the general population. Because frequency can vary significantly between different ancestral groups, researchers often look at data from diverse cohorts to ensure that risk assessments are accurate across all populations. If you are reviewing your own genetic data, it is helpful to remember that a variant's frequency does not necessarily dictate its clinical importance; rather, it provides context for how common that specific genetic signature is within the human gene pool.
Interpreting Your Results
If you have encountered rs4986850 in a genetic report, it is important to approach the information with perspective. This variant is not a diagnostic tool for breast cancer. Because the evidence for its individual impact is limited, it should not be used to make medical decisions or to assess personal risk in isolation. Genetic risk scores are complex and are best interpreted by a certified genetic counselor or a healthcare professional who can integrate your family history, lifestyle, and other clinical factors. You cannot change your genotype, but understanding your broader health profile can help you and your doctor make informed decisions about screening and preventative care. Always consult with a medical professional before drawing conclusions about your health based on individual genetic markers.
How common is this variant?
The GMAF for rs4986850 is 0.03949, indicating it is a relatively rare variant across global populations.
Frequently asked questions
Does having the rs4986850 variant mean I will get breast cancer?
No. This variant is associated with a very small, statistical contribution to cumulative risk and is not a diagnostic marker for breast cancer.
Is rs4986850 the same as a BRCA1 mutation?
No. rs4986850 is a common genetic variant, whereas the well-known BRCA1 mutations that significantly increase cancer risk are typically rare, high-impact pathogenic variants.
Should I be worried if I have the GG genotype?
There is no reason for alarm. This variant has limited evidence of clinical impact, and genetic risk is determined by the combination of many factors, not a single SNP.
How can I use this information to lower my risk?
You should focus on established preventative measures, such as regular screenings and healthy lifestyle choices, and discuss your overall genetic risk profile with a healthcare provider.
Sources & further reading
Educational information only, last refreshed 9/17/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs4986850?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in BRCA1
This rare variant has been recently annotated in clinical databases as a potential contributor to hereditary breast and ovarian cancer risk.
Variant identified in polygenic risk scores for breast cancer susceptibility.
A rare variant located in the BRCA1 gene, relevant to reproductive genetic counseling and the assessment of hereditary cancer risk.
This variant is a rare genetic alteration in the BRCA1 gene, which is critical for DNA repair and associated with hereditary breast and ovarian cancer syndromes impacting reproductive health.
A very rare variant identified in recent genomic studies, currently being investigated for potential associations with reproductive phenotypes.
This BRCA1 variant (p.Pro871Leu) is a common polymorphism often evaluated in breast cancer risk studies, though it is generally considered to have no clinical significance for hereditary breast and ovarian cancer syndrome.